PRC
AIMT

Pearl River Capital’s Aimmune Therapeutics AIMT Stock Holding History

Pearl River Capital’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,228
Closed -$28K – 521
2019
Q1 		$28K Buy
+1,228
New +$28.9K 0.07% 276

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pearl River Capital's AIMT Position: Q2 2019 in Review

Pearl River Capital sold out of Aimmune Therapeutics (AIMT) in Q2 2019, closing a stake of 1,228 shares — an estimated $28K sold.

Pearl River Capital first reported a position in AIMT in Q1 2019 and held it in 1 quarter. The position peaked at $28K in Q1 2019. 125 funds tracked by Wall St. Rank hold AIMT as of Q2 2019.

  • Pearl River Capital reported no remaining Aimmune Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Pearl River Capital sold 1,228 Aimmune Therapeutics shares in Q2 2019, an estimated $28K.
  • Pearl River Capital first reported a position in Aimmune Therapeutics in Q1 2019 and held it in 1 quarter.
  • Pearl River Capital's Aimmune Therapeutics position peaked at $28K in Q1 2019.
  • 125 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2019.

Based on Pearl River Capital's 13F filing for Q2 2019, filed 12 Aug 2019.